Biofrontera AG
0DOL.L
London Stock Exchange2.27
EUR
-0.13
- -
Biofrontera AG
0DOL.L
(London Stock Exchange)
Recent
price
2.27
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biofrontera AG, a biopharmaceutical company specializing in the development, manufacture and commercialization of dermatological drugs and medical cosmetics for the treatment of skin conditions, focuses on photodynamic therapy products including its lead prescription gel Ameluz (5-aminolevulinic acid 78mg/g) for mild to moderate actinic keratosis on the face and scalp, field cancerization and superficial basal cell carcinoma; proprietary red-light lamps BF-RhodoLED and RhodoLED XL emitting at 635nm for PDT illumination of larger areas with adjustable intensity and fan for patient comfort; and dermocosmetics line Belixos Active Care foam incorporating mahonia for soothing irritated, itchy skin in atopic dermatitis, psoriasis and daily care. Founded in 1997 and headquartered in Leverkusen, Germany, the company operates through subsidiaries Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH and Biofrontera Neuroscience GmbH, with sales organizations in Spain via Biofrontera Pharma GmbH sucursal en España and in the United Kingdom via Biofrontera UK Ltd; it markets Ameluz and BF-RhodoLED directly in Germany, Spain and the UK, supplies license partners in other European countries including Austria, Switzerland, Scandinavia, Poland, and formerly the US via Biofrontera Inc., and Asia-Pacific via Maruho Co. Ltd under a 2020 exclusive license. Biofrontera AG reports sales across Germany (50%), US (29%), Spain (11%) and UK (6%) in H1 2025, with Ameluz achieving 73% market share in German PDT, 52% in Spain and 49% in UK. Recent developments include a June 2025 binding term sheet with Biofrontera Inc. for strategic restructuring, transferring all US Ameluz and RhodoLED assets, rights, NDA, patents and personnel effective June 1 2025 in exchange for 10% equity stake and 12-15% ongoing US sales license fees, funded by $11 million investment and closing in October 2025; approval extensions for Ameluz with artificial daylight in Switzerland (April 2025) and propylene glycol-free formulation rollout; UK MHRA approval of promoted corticosteroid Ovixan (mometasone) via Galenica with marketing authorization transfer to Biofrontera Bioscience; promotion agreements with LEO Pharma for Advantan corticosteroid and Skinoren acne/rosacea treatments in Germany (August 2024); US FDA approvals for increased Ameluz dosage to three tubes and expanded skin area (September 2024), RhodoLED XL launch (2024); completion of Phase II acne and peripheral AK trials, Phase III sBCC and trunk/extremities AK studies; and US patent grant for propylene glycol-free Ameluz.